Introduction
The development of advanced imaging methods for detecting haemophilic joint disease has paralleled advances in treatment. There is hope that genetic manipulation may cure or alter the expression of recurrent bleeding episodes [1] . In the meantime, there are logistic and economic issues related to prophylaxis [2, 3] . Magnetic resonance imaging (MRI) can help in determining the stage of the joint disease and the selection of patients for prophylaxis, ie MRI can tell whether there is active bleeding in the joint, chronic synovitis with effusion or fibrosis with a contracted joint.
Animal studies have shown that the earliest effect of bleeding in the joint is on the articular cartilage [4] . However, in clinical practice the earliest changes that can be seen on imaging are in the synovium [5] . Recurrent bleeding tends to occur in predictable patterns. Most people with severe haemophilia have multiple target joints that tend to bleed asymmetrically and episodically so that, over time, one joint may stop bleeding and another commence. The common target joints are the knee, ankle and elbow.
Traditional imaging methods
Treatment options at all stages of disease may be influenced by imaging findings [6, 7] . In order to stage the progression of joint disease and select the appropriate therapy, two imaging classification systems of haemophilic joint disease were developed in the 1970s [8, 9] . These systems depend on the presence of abnormalities on conventional radiographs. The Arnold-Hilgartner scale, frequently used in the USA, is progressive in the sense that the final score is given for the worst findings in the joint as one advances through the stages of the disease (Table 1) . On the other hand, the Pettersson score, part of a detailed clinical and radiological classification of the haemophilic joint that was adopted by the World Federation of Haemophilia, is additive (Table 2) . This means that joint abnormalities at various stages may be present at the same time in a single target joint, and the presence of a more advanced disease finding does not preclude the presence of an earlier finding. For example, patients with cartilage loss are considered to be at an advanced stage of the disease in both scoring systems. However, the Pettersson system would generate a higher score for patients who have cysts and erosions in addition to cartilage loss than for those with only end-stage cartilage loss. Also, the Pettersson system does not attempt to evaluate the presence of soft tissue changes because of the difficulties inherent in trying to separate out various soft tissues that have similar physical densities on conventional radiographs. Therefore, no comment is made about the possibility of a joint effusion or synovitis. A modification of these plain film scores was proposed in 1989 that claimed to be as sensitive as the Pettersson method but simpler to use [10] . However, in practice, physicians tend to use the two earlier scoring methods.
Advanced imaging modalities
Radionuclide studies in the form of bone scans have been used to survey for the presence of inflammation around peripheral joints [11, 12] . This method allows a quick look at the entire skeleton but lacks spatial resolution. Bone mineral density studies with quantitative computed tomography or dual-energy X-ray scanning will show decreased bone density either from chronic illness or relative immobilization. Studies in children with haemophilia have looked at the effects of osteoporosis [13] . Sonography of the joints is a technology that has enjoyed more popularity in Europe and Canada than it has in the USA [14, 15] . It has the advantages of being cheap, easily incorporated into an office practice and noninvasive. The main disadvantages are that it takes considerable experience to become expert using this Ôhands-onÕ technology, and spatial and tissue resolution are not as good as MRI. Sources of error in musculoskeletal ultrasound have been documented [16] .
MRI offers an appealing alternative as an imaging modality. Many studies have reported on the efficacy of imaging haemophilic joint disease with MRI [17] [18] [19] . Specific injuries better seen with MRI include joint effusion/haemarthrosis, synovial hyperplasia/haemosiderin deposition, marginal erosions/ subchondral cysts and, to some degree, articular cartilage loss/degenerative joint disease.
MRI parameters
Blood products have variable MR signal depending on the age of the bleeding event. Very early bleeding may have a high signal on T1 and T2 weighted images. As the blood ages it becomes deposited in the synovial lining as haemosiderin, which has a low signal on both T1 and T2 [20] . In order to enhance the conspicuity of haemosiderin, and to allow adequate visualization of articular cartilage, gradient echo imaging of these joints has been advocated by Rand et al. [21] . The magnetic susceptibility artifact that is present in gradient echo images causes ironcontaining substances to appear intensely black (low signal). These same authors also wrote about the utility of intravenous gadolinium contrast enhancement for seeing the effects of synovitis, both in terms of the synovial hypertrophy and the production of joint fluid [21] .
Joint effusion/haemarthrosis
Most joint effusions will have MR signal characteristics of water, with low signal on T1 images and high signal on T2 (Fig. 1 ). As mentioned above, bleeding in the joint may be distinguished from water by the fact that acute bleeding may have the characteristic of being high signal on both T1 and T2. On gradient echo imaging it may be possible to Adapted from [9] . Adapted from [8] .
distinguish blood in the joint fluid from nonhaemorrhagic synovial fluid by the lower signal of blood ( Fig. 2 ).
Synovial hyperplasia/haemosiderin deposition
The key to the successful early treatment of haemophilic joint disease is the recognition of synovial hyperplasia. This can develop after only one or a few bleeding episodes. The amount of synovial hypertrophy can be quantified, although this is not easy. Methods of quantification usually involve drawing a region of interest measurement (an area) on a given MR slice. These areas can then be summed on contiguous slices to form a volume estimate [22] . As an alternative to this, a semiquantitative Denver scale has been developed to describe the various components of haemophilic joint disease [23] (Table 3) . Synovial hyperplasia is ranked as Ôabsent, small, moderate or largeÕ on the MR slice showing the most severe findings (Figs 3 and 4) . Most of these synovial deposits have haemosiderin within them. This fact is in contrast to what is seen in most other synovial inflammatory processes, such as juvenile rheumatoid arthritis. Prognostically, the presence or absence of haemosiderin does not appear to be as important as the amount of synovial hyperplasia that is present.
Marginal erosions/subchondral cysts
As mentioned above, blood in the joint has an early adverse effect on articular cartilage and marginal bone. Similar to rheumatoid arthritis, erosions can occur either before or at the same time that the articular cartilage is destroyed (Fig. 5) . Subchondral cysts develop because of the intrusion of synovium through fissures in the articular cartilage. Some of the cysts contain only fluid (Fig. 6 ), while others have irregular low-signal areas that are presumably synovium (Fig. 7) . In terms of quantifying these changes, the Denver score mentioned above uses the terms ÔpartialÕ and ÔfullÕ surface erosions, defined as less than 50% of the transverse articular surface of the joint affected on a coronal image in the case of partial erosions, and 50% or greater involvement in the case of full surface erosions. ÔOneÕ or Ômore than oneÕ subchondral cysts are ranked separately [23] .
Articular cartilage loss/degenerative joint disease
These findings are usually well seen on conventional radiographs and form part of the grading systems developed by Arnold-Hilgartner and Pettersson. Early stages of articular cartilage loss may be difficult to see both on radiographs and MRI. Various MR methods have been developed for visualizing cartilage [24, 25] . We prefer gradient echo imaging because it is fast, has adequate spatial resolution, can be obtained on most clinical MR scanners and can show haemosiderin and articular cartilage (Fig. 8) .
In young patients, where the secondary epiphyseal growth cartilage is large, it may be difficult to tell the enchondral cartilage of the secondary ossification centre from the overlying articular cartilage, but gradient echo imaging seems to be useful. In terms of grading the severity of the articular destruction, plain films are valuable. The Denver MRI score defines Ôcartilage lossÕ as less than 50% loss of the expected height of the joint space on a coronal image of the joint for a moderate change and 50% or greater loss for a severe change [23] .
In what clinical situations is MRI useful or necessary?
Before the development of clinically evident arthropathy, MRI findings can be used to select patients for early prophylaxis. This is especially helpful as part of a research study to compare various early treatment regimens [26] . Later in the development of the disease MRI can confirm the presence of synovitis and distinguish bleeding that is either inside or outside the joint. If arthropathy has developed to the stage where surgical intervention is being considered, MRI can confirm the severity of the synovitis or help in the decision to employ radiosynoviorthesis, although one study questioned the value of this evaluation [23] . Prior to surgery, some insurance plans require MRI or arthrography to confirm the severity of the disease. In older patients with advanced disease MRI can distinguish hypertrophied synovium from late degenerative changes. As mentioned above, haemosiderin may remain in the damaged joint for a long time, and MRI cannot detect ÔactivityÕ of the synovitis. Intravenous gadolinium contrast may aid in this distinction [21] .
Problems with the radiographic scoring systems that need to be resolved Each of the current scoring systems has issues that could be clarified. In the Arnold-Hilgartner scale ( (Table 2) . ÔIrregular subchondral surfaceÕ is defined as Ôpartly involvedÕ or Ôtotally involvedÕ. Does this mean that the cartilage has been eroded and the joint space narrowed? Do ÔerosionsÕ of the articular surface produce this ÔirregularÕ surface? ÔNarrowing of joint spaceÕ uses the terms Ôgreater thanÕ or Ôless than 1 mmÕ. These numbers would not apply in a young child. ÔSubchondral cyst formationÕ may be difficult to separate from erosions. If there are multiple small cysts along the articular surface, some with large openings on the articular surface, how do we decide whether to call these cysts or erosions? Are we scoring the same phenomenon twice? ÔErosions at joint marginsÕ presumably refers to the ÔmedialÕ and ÔlateralÕ edges of a joint, ie the bare areas. Do ÔpartialÕ and Ôfull surfaceÕ erosions refer to cartilage loss in a horizontal or a vertical direction? If the cartilage is worn away completely along the margin of a joint, is this erosion in addition to cartilage loss? ÔGross incongruence of articulating bone endsÕ can be slight or pronounced. How can something gross also be slight? Does ÔincongruenceÕ mean translation or subsidence of one of the articular surfaces relative to the other or something else? ÔJoint deformity (angulation and/or displacement between articulating bones)Õ sounds the same as gross incongruence.
Problems with the MRI scoring system that need to be resolved
The Denver MRI scale will also benefit from further clarification. ÔEffusionÕ and Ôsynovial hyperplasiaÕ are critical MRI findings (Table 3) . Can we quantify them more precisely? Is it important to distinguish ÔhaemarthrosisÕ from ÔeffusionÕ? Should haemosiderin deposition be counted as a finding separate from synovial hyperplasia? Cartilage loss is easy to detect in adults; in young children, it may be difficult to tell articular cartilage and immature growth cartilage apart. Extraneous findings, such as pseudotumour, osteonecrosis, ligament tear and loose bodies are recorded, but are not used as part of the joint score (Table 3 ). Should they be included in the score?
Conclusion
MRI will play an important role in staging patients for appropriate treatment of haemophilic joint disease. There is need for a consensus on how these joints should be imaged and how they should be scored so that the results of treatment regimens can be compared between various medical centres. Better ways to quantify the degree of abnormality will be useful.
Open discussion following the presentation by Dr Ray Kilcoyne Dr Carlos Rodriguez-Merchan: Have you made any comparison study between the radiological classification system of Pettersson and your magnetic resonance imaging (MRI) classification?
Dr Kilcoyne: In terms of sensitivity, we know that MRI is much more sensitive because we are looking at soft tissue changes, which are excluded in the Pettersson scale, so in that regard they are different. For more advanced disease with bone changes, many times you can see the cysts equally well on plain films, and I think sometimes you can see the erosions better. I don't have a statistical study to show that MRI is better, but with the advanced bone changes, sometimes the X-ray is better than MRI.
Dr Marilyn Manco-Johnson: You allude to the fact that osteoporosis may not be an important finding. Do you think that for the purpose of preventing arthropathy, we should be interested in anything other than cysts, erosions and cartilage narrowing?
Dr Kilcoyne: Based on my experience with imaging rheumatoid arthritis, I don't know that finding early bone changes that are easily reversible on X-ray really has any meaning in terms of predicting who is going to progress. But I think that finding synovitis and joint effusion and knowing why the joint is boggy on physical exam can also be useful.
Dr Marilyn Manco-Johnson: Do you think that ultrasound would help in looking at synovitis?
Dr Michael Manco-Johnson: You may be able to measure the quantity of synovium much better with ultrasound than you can with MRI. But it is also more confusing, because it is a technically difficult exam.
Dr Rolf Ljung: The proposed Denver score has been tested on a small scale in our paediatric network, and one of the ideas they had with that score was to separate irreversible from reversible changes, and perhaps use the score for reversible changes to optimize treatment. In terms of additive or progressive scales, it could be sometimes one is more useful than the other, depending on what you're going to use the score for.
Dr Kilcoyne: I would agree with that. The reversible changes would be joint effusion and synovial proliferation.
Dr Marilyn Manco-Johnson: We don't know yet whether synovial hyperplasia is reversible or not.
Dr Victor Blanchette: When you look at young boys with severe haemophilia whose joints you have studied where there has not been a reported history of a bleed, how many times do you see abnormalities on MRI, and what are the abnormalities that you do see?
Dr Kilcoyne: These children we are imaging are in the prophylaxis study, and I am blinded to their history. Many children have completely normal joints before the age of 2 years. In some we might see a small effusion or a tiny bit of synovium where I might equivocate and say I'm not sure if that is synovium. But I can't put that into a clinical context, because I don't have the information.
Dr Marilyn Manco-Johnson: On the baseline evaluation before the children were randomized, we noted that about 10% of children had a tiny shadow that could have been either fat or a tiny bit of synovium. There was no correlation with the parents' records of possible joint bleeds. We won't know more until they get to be age 6: if it goes away, maybe it was not significant; if it progresses, maybe it was. We are hoping, too, that the joints without clinical bleeds will be normal on the MRI and that will correlate with the physical assessment, so that in the future, we'll be able to say if it looks normal and you have not had a bleed, don't worry about it.
Dr Alessandro Gringeri: In your opinion, will MRI be something useful for clinical trials or also in clinical practice?
Dr Kilcoyne: I think it is an exciting and very useful tool, but I don't want to oversell it. Let's suppose you have a child who is said to have bleeding in a joint every couple of weeks and is getting replacement factor, and you don't think that is the correct diagnosis, MRI is certainly the best way to show whether there is fluid or synovium in the joint. I think it would be used to investigate the problem cases in clinical practice, the patients who are not responding, or the ones who are difficult to diagnose.
Dr Marilyn Manco-Johnson: In terms of clinical use, if we have a plan to start prophylaxis with the first joint bleed, sometimes it helps convince the parent if we do the MRI and see if it's fluid, and maybe an ultrasound would work there, too. If an adult is using a lot of factor and we think it's for arthritic pain, we get the MRI and show them that there's no haemosiderin, so there can't have been blood. In patients with inhibitors, we do it frequently. If we can't control the bleeding perfectly, we will get it to detect synovial hyperplasia and do a (32)P injection earlier rather than later to try to prevent progression of the joint disease.
